HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
The publication reports results of the randomized, placebo-controlled 12-week study to assess efficacy, safety and tolerability of HTD1801 compared to placebo in patients with T2DM. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 12 with HTD1801 versus placebo. A majority of patients treated with HTD1801 achieved target HbA1c <7%. Further, results show therapeutic benefit of HTD1801 on LDL and total cholesterol, markers of liver injury and systemic inflammation. In this study, HTD1801 was well tolerated with no treatment-related serious adverse events observed. These findings are being confirmed in ongoing Phase 3 studies.
'We are encouraged by the results of this Phase 2 study. The study provides evidence that HTD1801 can treat the core aspects of metabolic syndrome, with potential to provide a spectrum of therapeutic effects that appear to address comorbid conditions that exacerbate disease and worsen prognosis of patients with T2DM,' said Dr. Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People's Hospital, in Beijing, China.
'Based on these positive findings, we are continuing to advance the clinical development of HTD1801 in our ongoing Phase 3 T2DM program with topline results expected in the first half of this year,' said Dr. Liping Liu, CEO of HighTide Therapeutics.
About JAMA Network Open Journal
JAMA Network Open is an international, peer-reviewed, open access, general medical journal that publishes research on clinical care, innovation in health care, health policy, and global health across all health disciplines and countries for clinicians, investigators, and policy makers. JAMA Network Open is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
About Berberine Ursodeoxycholate (HTD1801)
Berberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with unique dual mechanisms of action, including AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in glucose metabolism, insulin resistance, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases such as T2DM.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indication potential across multiple metabolic and digestive diseases with significant unmet medical needs. The Company is currently developing several clinical assets and holding global intellectual property rights, advancing multiple mid-to-late-stage clinical trials including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the Company's lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 hours ago
- Business Wire
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025 Share Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit SOURCE: Hologic, Inc.
Miami Herald
16 hours ago
- Miami Herald
FDA chocolate recall warns of ‘serious or life-threatening' risk
Americans eat an estimated 2.8 billion pounds of chocolate each year, which isn't surprising, given how many delicious forms the sweet treat comes in. That rounds out to around 11 pounds per person of chocolate each year. We don't hold the title for the most chocolate consumed, though. That belongs to the Swiss, although the United States does produce more chocolate than any other country in the world. Don't miss the move: Subscribe to TheStreet's free daily newsletter The FDA has strict production standards for the chocolate that U.S. companies produce and sell, including regulating the minimum amount of cocoa solids that have to be present in chocolate for the products to carry the chocolate label. Beyond production issues, there are also many other rules in place to make sure people are not sickened by the chocolate they consume. Unfortunately, one company has failed to live up to these obligations recently, and its lapse is putting chocolate eaters at risk. The FDA recently issued an urgent safety recall. The chocolate company originally alerted customers on June 25, 2025, and the FDA published it on June 30, 2025, in order to sound the alarm to the public as a whole and make sure word got out. The FDA warned that the recall was a very serious one, with potentially life-threatening consequences. The recalled items were made by the Mellace Family Brands California, Inc. of Warren, Ohio, and include Wegmans Semi-Sweet Chocolate Nonpareils. The affected items were distributed through Wegmans grocery stores in eight different states: DelawareMarylandMassachusettsNorth CarolinaNew JerseyNew YorkPennsylvaniaVirginiaWashington D.C. The problem with the candies that prompted the recall is an undeclared allergen. It was discovered that the Nonpareils contained a milk allergen and were distributed in packaging that did not alert consumers to the presence of this ingredient. Related: CDC sounds the alarm on growing global travel concern A temporary breakdown in the supplier's manufacturing process caused the problem to occur, and as the FDA alert makes clear, "people who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product with the lot codes shown below." Fortunately, the issue was discovered before anyone had an allergic reaction and suffered health consequences. Customers who bought the affected items are now being urged to return them to the place where they were purchased to obtain a full refund. The impacted candies were sold in a plastic tub and include items with the following lot codes: 55021 BEST BY: DEC 28, 202555031 BEST BY: DEC 29, 202555491 BEST BY: FEB 13, 202655501 BEST BY: FEB 14, 202656061 BEST BY: APR 11, 202656071 BEST BY: APR 12, 2026 You can find your lot code and best by date on the left side of the candy tub. In 2024, 2,454 product recalls had already occurred in the United States across five key industries by the third quarter of the year, according to Sedgwick. These recalls affected a total of 580.4 million products. The five industries include medical devices, food, pharmaceuticals, consumer products, and automotive. Related: TSA issues stern warning forbidding popular summer item Food saw a 112.7% increase in recalls in 2024 year, a disturbing number for those who expect and hope the products they consume will be safe. Consumers should monitor the FDA for news of recalls to make sure they do not have affected products. The FDA has a searchable database of safety alerts online to help make that easier, with Wegman's chocolate products currently topping the list as the most recent recall. More Retail: Walmart CEO sounds alarm on a big problem for customersTarget makes a change that might scare Walmart, CostcoTop investor takes firm stance on troubled retail brandWalmart and Costco making major change affecting all customers Hopefully, consumers with serious milk allergies will see the news of the chocolate recall and return the items before any harm is done. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Indianapolis Star
17 hours ago
- Indianapolis Star
Viemed Completes Acquisition of Lehan's Medical Equipment Anticipates Updating its Full Year 2025 Outlook for the Acquisition with Second Quarter 2025 Financial Results
LAFAYETTE, LA / ACCESS Newswire Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has completed the previously disclosed acquisition of Illinois-based Lehan's Medical Equipment ('Lehan') for a base purchase price of $26 million, subject to customary adjustments, plus estimated contingent payments of $2.2 million. 'We are pleased to close the acquisition of Lehan and bring this talented and highly motivated team into the Viemed family,' said Viemed Chief Executive Officer Casey Hoyt. 'Lehan's 80-year track record and brand recognition in a large and fast-growing market along with its preferred contracts and fulfillment expertise make for a powerful combination with our national scale, unique care delivery model and existing payer relationships to serve a broader patient population.' In 2024, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million. See 'Non-GAAP Financial Measures' for a discussion of Adjusted EBITDA. Viemed funded the acquisition through a combination of cash on hand and borrowings from its existing credit facilities. Viemed anticipates increasing its previously issued full-year 2025 guidance range to account for the expected contribution from this acquisition when it reports earnings results for the quarter ended June 30, 2025. Lehan's Medical Equipment is a healthcare provider offering home medical equipment and products for women's health, including breast pumps. The organization specializes in promoting wellness through a variety of healthcare services. Lehan also provides rental, sales, and resupply of CPAPs and other respiratory devices, as well as sales of other medical equipment. Lehan currently has three full-service locations in the Northern Illinois area and three sleep/CPAP set up locations in the West Chicagoland area, including one in Wisconsin. ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Investor Relations ir@ Tripp Sullivan SCR Partners, LLC 615-942-7077 Trae Fitzgerald Chief Financial Officer Viemed Healthcare, Inc. 337-504-3802 Forward-Looking Statements Certain statements contained in this press release may constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'potential', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'projects', or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results 'will', 'should', 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations about its acquisition of Lehan's Medical Equipment, such as contingent payments, anticipated benefits, and anticipated updates to the Company's 2025 financial guidance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the 'SEC') available on the SEC's website at including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. Non-GAAP Financial Measures This press release refers to 'Adjusted EBITDA' which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of Adjusted EBITDA may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and other adjustments, including adjustments relating to the proposed acquisition of Lehan. Company management believes Adjusted EBITDA provides helpful information to analyze Lehan's operating performance, including a view of Lehan's business that is not dependent on the impact of Lehan's capitalization structure and the exclusion of items that are not part of Lehan's recurring operations, including the impacts of the Company's proposed acquisition of Lehan. Accordingly, Company management believes that Adjusted EBITDA provides useful information in understanding and evaluating Lehan's historical operating performance in the same manner as it analyzes the Company's operating performance. SOURCE: Viemed Healthcare, Inc.
